Does the 0.25 Put/Call Ratio for VSTM reflect bullish sentiment on AVMAPKI FAKZYNJA CO-PACK launch?

A Put/Call Ratio (PCR) of 0.25 for VSTM indeed reflects a strong bullish sentiment in the options market. A ratio below 1 indicates that more call options (bets on a stock price increase) are being traded than put options (bets on a stock price decrease). A value as low as 0.25 suggests a significant leaning towards bullish expectations among options traders.

This bullish sentiment appears to align with the recent positive developments surrounding Verastem Oncology's (VSTM) AVMAPKI™ FAKZYNJA™ CO-PACK. The U.S. Food and Drug Administration (FDA) granted accelerated approval for the AVMAPKI™ FAKZYNJA™ CO-PACK on May 8, 2025, for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer. This approval came well ahead of its Prescription Drug User Fee Act (PDUFA) action date of June 30, 2025, and marks the first-ever FDA-approved treatment specifically for this disease. The product was expected to be commercially available in the U.S. within one week of the approval, and Verastem markets the AVMAPKI™ FAKZYNJA™ CO-PACK in the U.S.

Given the significance of this product launch as the first and only FDA-approved medicine for this indication, it is highly probable that the market's strong bullish sentiment, as indicated by the low Put/Call Ratio, is a direct reflection of positive expectations regarding the commercial success and revenue generation from the AVMAPKI™ FAKZYNJA™ CO-PACK.